NCT04935853Recruiting
Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study
Marqueurs Pronostiques et prédictifs de réponse Aux Traitements Chez Les Patients Atteints de Cancer Des Voies Biliaires : Cohorte Multicentrique ACABi PRONOBIL
Source: ClinicalTrials.gov · Last updated 23 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy, targeted therapy,loco-regional treatments ) in patients with bile duct cancer. The effectiveness and tolerance of these treatments in current practice will also be evaluated.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1350 (estimated)
- First submitted
- 28 May 2021
- Start date
- 23 May 2022
- Primary completion date
- 1 Jun 2030
- Lead sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT04935853
What you commit to
- Study type: Observational
- Planned participants: 1350
- From 23 May 2022 to the primary completion date, 1 Jun 2030
- 32 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patient under guardianship, curatorship or legal protection
- Pregnant or breastfeeding women
- Any medical, psychological or social situation, which could prevent the compliance with the protocol according to the investigator's assessment
- Refusal to participate in the study
Who the study is looking for
- All locations of primitives (intrahepatic CCA, extrahepatic CCA, adenocarcinoma of the gallbladder; ampullomas excluded)
- Age \> 18 years
- Diagnosed between 2003 and 2030 (minimum follow-up 2 years)
- Written written non-opposition +/- signed informed consent for genetic studies (N.B.:
- exemption requested for a deceased patient) N.B. Authorized inclusion in a therapeutic research protocol
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (32)
Sites in registry order. Pick your city on the disease page to sort them by distance.
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.